|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stenmark H: Rab GTPases as coordinators of
vesicle traffic. Nat Rev Mol Cell Biol. 10:513–525. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reiner DJ and Lundquist EA: Small GTPases.
WormBook 1.67.2. 1–99. 2016.
|
|
5
|
Hou R, Jiang L, Yang Z, Wang S and Liu Q:
Rab14 is overexpressed in ovarian cancers and promotes ovarian
cancer proliferation through Wnt pathway. Tumour Biol.
37:16005–16013. 2016. View Article : Google Scholar
|
|
6
|
Sun J, Feng X, Gao S and Xiao Z:
microRNA-338-3p functions as a tumor suppressor in human
non-small-cell lung carcinoma and targets Ras-related protein 14.
Mol Med Rep. 11:1400–1406. 2015. View Article : Google Scholar
|
|
7
|
Yu J, Wang L, Yang H, Ding D, Zhang L,
Wang J, Chen Q, Zou Q, Jin Y and Liu X: Rab14 suppression mediated
by miR-320a inhibits cell proliferation, migration and invasion in
breast cancer. J Cancer. 7:2317–2326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Liu H, Shao J and Xing G: miR-320a
serves as a negative regulator in the progression of gastric cancer
by targeting RAB14. Mol Med Rep. 16:2652–2658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo B, Wang W, Zhao Z, Li Q, Zhou K, Zhao
L, Wang L, Yang J and Huang C: Rab14 act as oncogene and induce
proliferation of gastric cancer cells via AKT signaling pathway.
PLoS One. 12:e01706202017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valeri N, Croce CM and Fabbri M:
Pathogenetic and clinical relevance of microRNAs in colorectal
cancer. Cancer Genomics Proteomics. 6:195–204. 2009.PubMed/NCBI
|
|
12
|
Shen Z, Zhou R, Liu C, Wang Y, Zhan W,
Shao Z, Liu J, Zhang F, Xu L, Zhou X, et al: MicroRNA-105 is
involved in TNF-α-related tumor microenvironment enhanced
colorectal cancer progression. Cell Death Dis. 8:32132017.
View Article : Google Scholar
|
|
13
|
Shen ZL, Wang B, Jiang KW, Ye CX, Cheng C,
Yan YC, Zhang JZ, Yang Y, Gao ZD, Ye YJ, et al: Downregulation of
miR-199b is associated with distant metastasis in colorectal cancer
via activation of SIRT1 and inhibition of CREB/KISS1 signaling.
Oncotarget. 7:35092–35105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Shen ZL, Gao ZD, Zhao G, Wang CY,
Yang Y, Zhang JZ, Yan YC, Shen C, Jiang KW, et al: miR-194,
commonly repressed in colorectal cancer, suppresses tumor growth by
regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle.
14:1046–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang B, Shen ZL, Jiang KW, Zhao G, Wang
CY, Yan YC, Yang Y, Zhang JZ, Shen C, Gao ZD, et al: MicroRNA-217
functions as a prognosis predictor and inhibits colorectal cancer
cell proliferation and invasion via an AEG-1 dependent mechanism.
BMC Cancer. 15:4372015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang LY, Liu M, Li X and Tang H:
miR-490-3p modulates cell growth and epithelial to mesenchymal
transition of hepatocellular carcinoma cells by targeting
endoplasmic reticulum-Golgi intermediate compartment protein 3
(ERGIC3). J Biol Chem. 288:4035–4047. 2013. View Article : Google Scholar :
|
|
17
|
Shen J, Xiao Z, Wu WK, Wang MH, To KF,
Chen Y, Yang W, Li MS, Shin VY, Tong JH, et al: Epigenetic
silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1
to promote Helicobacter pylori-induced gastric carcinogenesis.
Cancer Res. 75:754–765. 2015. View Article : Google Scholar
|
|
18
|
Qu M, Li L and Zheng WC: Reduced
miR-490-3p expression is associated with poor prognosis of
Helicobacter pylori induced gastric cancer. Eur Rev Med Pharmacol
Sci. 21:3384–3388. 2017.PubMed/NCBI
|
|
19
|
Chen S, Chen X, Xiu YL, Sun KX and Zhao Y:
MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial
carcinoma tumori-genesis and progression. Cancer Lett. 362:122–130.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S,
Cheng K and Zou W: miR-490-3p inhibits the growth and invasiveness
in triple- negative breast cancer by repressing the expression of
TNKS2. Gene. 593:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu W, Xu G, Liu H and Li T:
MicroRNA-490-3p regulates cell proliferation and apoptosis by
targeting HMGA2 in osteo-sarcoma. FEBS Lett. 589B:3148–3153. 2015.
View Article : Google Scholar
|
|
22
|
Xu X, Chen R, Li Z, Huang N, Wu X, Li S,
Li Y and Wu S: MicroRNA-490-3p inhibits colorectal cancer
metastasis by targeting TGFβR1. BMC Cancer. 15:10232015. View Article : Google Scholar
|
|
23
|
Zheng K, Zhou X, Yu J, Li Q, Wang H, Li M,
Shao Z, Zhang F, Luo Y, Shen Z, et al: Epigenetic silencing of
miR-490-3p promotes development of an aggressive colorectal cancer
phenotype through activation of the Wnt/β-catenin signaling
pathway. Cancer Lett. 376:178–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ: Schmittgen TD. Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)). Method Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvi-ronment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Profumo V and Gandellini P: MicroRNAs:
Cobblestones on the road to cancer metastasis. Crit Rev Oncog.
18:341–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen Z, Wang B, Luo J, Jiang K, Zhang H,
Mustonen H, Puolakkainen P, Zhu J, Ye Y and Wang S: Global-scale
profiling of differential expressed lysine acetylated proteins in
colorectal cancer tumors and paired liver metastases. J Proteomics.
142:24–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Doldi V, Pennati M, Forte B, Gandellini P
and Zaffaroni N: Dissecting the role of microRNAs in prostate
cancer metastasis: Implications for the design of novel therapeutic
approaches. Cell Mol Life Sci. 73:2531–2542. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
White NM, Fatoohi E, Metias M, Jung K,
Stephan C and Yousef GM: Metastamirs: A stepping stone towards
improved cancer management. Nat Rev Clin Oncol. 8:75–84. 2011.
View Article : Google Scholar
|
|
31
|
Gandellini P, Doldi V and Zaffaroni N:
microRNAs as players and signals in the metastatic cascade:
Implications for the development of novel anti-metastatic
therapies. Semin Cancer Biol. 44:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka
H, Boland CR and Goel A: Circulating microRNA-203 predicts
prognosis and metastasis in human colorectal cancer. Gut.
66:654–665. 2017. View Article : Google Scholar
|
|
33
|
Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang
DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al: Identification
of microRNA-214 as a negative regulator of colorectal cancer liver
metastasis by way of regulation of fibroblast growth factor
receptor 1 expression. Hepatology. 60:598–609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tian J, Xu YY, Li L and Hao Q: miR-490-3p
sensitizes ovarian cancer cells to cisplatin by directly targeting
ABCC2. Am J Transl Res. 9:1127–1138. 2017.PubMed/NCBI
|
|
35
|
Takai Y, Sasaki T and Matozaki T: Small
GTP-binding proteins. Physiol Rev. 81:153–208. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jung B, Staudacher JJ and Beauchamp D:
Transforming growth factor β superfamily signaling in development
of colorectal cancer. Gastroenterology. 152:36–52. 2017. View Article : Google Scholar
|
|
37
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kinzler KW and Vogelstein B: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang JL, Qi Z, Li YH, Zhao HM, Chen YG and
Fu W: TGFβ induced factor homeobox 1 promotes colorectal cancer
development through activating Wnt/β-catenin signaling. Oncotarget.
8:70214–70225. 2017.PubMed/NCBI
|
|
40
|
Ma F, Li W, Liu C, Li W, Yu H, Lei B, Ren
Y, Li Z, Pang D and Qian C: miR-23a promotes TGF-β1-induced EMT and
tumor metastasis in breast cancer cells by directly targeting CDH1
and activating Wnt/β-catenin signaling. Oncotarget. 8:69538–69550.
2017.PubMed/NCBI
|
|
41
|
Gillespie J, Ross RL, Corinaldesi C,
Esteves F, Derrett-Smith E, McDermott MF, Doody GM, Denton CP,
Emery P and Del Galdo F: Transforming growth factor β activation
primes canonical Wnt signaling through down-regulation of Axin-2.
Arthritis Rheumatol. 70:932–942. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitchell H, Choudhury A, Pagano RE and
Leof EB: Ligand- dependent and -independent transforming growth
factor-beta receptor recycling regulated by clathrin-mediated
endocytosis and Rab11. Mol Biol Cell. 15:4166–4178. 2004.
View Article : Google Scholar : PubMed/NCBI
|
